EN DE

IPOPEMA Securities S.A (IPE) Fair Value & Analysis

Financial Services · PL · Market cap 219M PLN

IS IPOPEMA Securities S.A IPE · WAR
Price9.20 PLN
Fair Value6.34 PLN
Upside-31.1%
Quality64/100
Watch IPOPEMA Securities S.A for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 9.8% net margin
Low debt · generates free cash flow
Mixed vs. peers (7/13)
Moderate moat 56/100
Evidence: High Range 4.76 PLN – 7.93 PLN Share as image

Fair value as of: Jul 16, 2026

From 13 valuation models · updated 25 days ago

Share price +24.3% over the past month.

A solid business, but screening 31% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (7.93 PLN). The favourable scenario is already priced in.
  • Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
  • For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

9.20 PLN 1.44 PLN Fair Value 6.34 PLN Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.

How to read this chart

60‑month range 1.44 PLN – 9.20 PLN · fair‑value band 4.76 PLN – 7.93 PLN · the 9.20 PLN price screens above the 6.34 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

IPOPEMA Securities S.A (IPE) currently trades at 9.20 PLN, while our model-based Fair Value estimate is 6.34 PLN, implying the stock looks roughly 31.1% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, IPOPEMA Securities S.A generated revenue of 269M PLN at a net margin of 3.4%. Revenue grew 21.6% year over year. It earns a return on equity of 8.3%. The balance sheet holds a net cash position of 171M PLN. Fundamentals as of Jul 16, 2026

Our scenario range runs from 4.76 PLN (bear case) to 7.93 PLN (bull case); at 9.20 PLN, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 258% above its 52-week low, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at 11% fair-value upside, at -31%, IPE screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 13.70 PLN 16.27 PLN 19.37 PLN 80
Residual Income 4.34 PLN 5.49 PLN 12.50 PLN 76
Rev-Margin DCF 14.22 PLN 18.69 PLN 24.00 PLN 74
All 13 models by family
DCF Models
Owner Earnings 14.60 PLN 18.03 PLN 22.46 PLN 31
5Y P/E Exit 13.68 PLN 17.66 PLN 21.88 PLN 38
10Y P/E Exit 13.60 PLN 16.75 PLN 20.67 PLN 35
Earnings-Based
Graham-Dodd 5.42 PLN 18.92 PLN 25.43 PLN 54
Lynch FV 4.40 PLN 6.29 PLN 8.17 PLN 50
Dividend Discount
Gordon GGM 1.46 PLN 2.45 PLN 3.18 PLN 70
DDM Multi-Stage 1.46 PLN 2.31 PLN 2.64 PLN 61
Multiples
P/E Multiple 7.77 PLN 10.36 PLN 12.95 PLN 63
P/B Multiple 4.76 PLN 6.34 PLN 7.93 PLN 55
Asset-Based
NCAV (Graham) 2.27 PLN 3.04 PLN 4.53 PLN 50
Growth DCF
Growth DCF 13.70 PLN 16.27 PLN 19.37 PLN 80
Rev-Margin DCF 14.22 PLN 18.69 PLN 24.00 PLN 74
Economic Profit
Residual Income 4.34 PLN 5.49 PLN 12.50 PLN 76

Widest divergence: DCF Models (17.66 PLN) versus Dividend Discount (2.31 PLN). Highest evidence: Growth DCF (80).

Notify me when IPE reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 269M PLN
Revenue growth (YoY) +21.6%
Net margin 3.4%
Return on equity 8.3%
Free cash flow 24.4M PLN FY2025
P/E ratio 6.8
More key figures
Operating margin 0.6%
EPS (TTM) 0.9900 PLN
Dividend yield 3.1%
EPS growth (YoY) +112%
Net cash 171M PLN FY2025

Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 64/100

Of which business quality 63 · Market factors (momentum, volatility) 92

Profitability 40
Margins and returns on capital today
Quality Growth 70
Are margins and returns improving?
Cashflow 55
Earnings quality: real cash, not paper profit
Fin. Strength 73
Balance sheet, leverage, solvency risk
Investment 73
Disciplined investing over empire-building
Low Volatility 73
Calm price path (market factor)
Momentum 100
Price trend over the last 3–12 months (market factor)
52W Momentum 100
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

IPOPEMA Securities S.A., together with its subsidiaries, provides brokerage, company analysis, and investment banking services in Poland.

Full company description

IPOPEMA Securities S.A., together with its subsidiaries, provides brokerage, company analysis, and investment banking services in Poland. The company engages in the brokerage and investment banking activities; distribution of investment products; and provision of investment advisory services to a range of individual investors, as well as advisory services related to corporate financial restructuring and financing for infrastructure projects. It also involves in the creation and management of investment funds; management of portfolios of brokerage financial instruments; business and management consulting; information technology facilities management; information technology consulting; and software-related activities. In addition, the company offers investment banking services, including preparation and execution of capital market transactions, public issues of securities, mergers and acquisitions (M&A) transactions, management buyouts, and advisory services for raising private market financing, as well as organizing buyback transactions for shares listed on the Warsaw Stock Exchange through public tender offers and buy-back programs. Further, it provides portfolio management services; securities trading advisory services; intermediation services; involved in the creation and management of closed-end and open-end investment funds; and wholesale of computers, peripherals, and software. IPOPEMA Securities S.A. was incorporated in 2005 and is based in Warsaw, Poland.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

IPOPEMA Securities S.A reported revenue of 297M PLN in FY2025 versus 256M PLN in FY2021, a compound +3.7%/yr. Reported net income was 23.9M PLN in FY2025, compounding +16.2%/yr from FY2021.

Growth Quality 69/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
297M PLN
Latest YoY
+15.5%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.5%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+2.8%
Avg. growth/yr (17Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+10.6%
Revenue +3.7%/yr
FY21 256M PLN
FY22 260M PLN
FY23 324M PLN
FY24 257M PLN
FY25 297M PLN
Net income +16.2%/yr
FY21 13.1M PLN
FY22 5.5M PLN
FY23 18.2M PLN
FY24 9.1M PLN
FY25 23.9M PLN
Character of growth · EPS growth decomposed (2014-2025) +19.9 % p.a.
Revenue per share +13.1 pp

of which total revenue +13.1 pp · buybacks/dilution +0.0 pp

EBIT margin +0.9 pp
Tax rate +1.0 pp
Residual (interest, one-offs) +4.9 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

IPE screens 31% overvalued. Compare with Huatai Securities Co →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "IPOPEMA Securities S.A Fair Value". https://www.fairvalue-calculator.com/stock/IPE

Peer Group

Capital Markets · 423 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 65 · Top 25%
Fair Value upside −31% · Below median
Return on equity (TTM) 23% · Top 25%
Return on assets 6% · Top 25%
Net margin (TTM) 10% · Below median
Operating margin (TTM) 8% · Below median
Revenue growth 17% · Below median
Dividend yield (TTM) 0.0% · Bottom 25%

Valuation Multiples vs Capital Markets median · lower = cheaper

P/E (TTM) 7.4× · Cheaper than 75% of peers
P/B 0.43× · Cheaper than 75% of peers
P/S (TTM) 0.19× · Cheaper than 75% of peers
P/FCF 2.4× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 9
FUTURE 83 · sector 96
PAST 91 · sector 30
HEALTH 100 · sector 93
DIVIDEND 0 · sector 36

VALUE 0: the price sits above our fair-value range.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Capital Markets stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).

Stock Price Fair Value vs Fair Value
Huatai Securities Co HTSC $0.2700 $0.0400 -85%
Mirae Asset Securities Co 006800 38,750 KRW 31,645 KRW -18%
Meritz Financial Group 138040 117,000 KRW 87,706 KRW -25%
Korea Investment Holdings 071050 239,000 KRW 318,825 KRW +33%
NH Investment & Securities Co 005940 31,000 KRW 37,133 KRW +20%
Samsung Securities Co 016360 107,700 KRW 126,487 KRW +17%
Motilal Oswal Financial Services Limited MOTILALOFS ₹967.00 ₹299.65 -69%
Kiwoom Securities Co 039490 322,000 KRW 358,091 KRW +11%
SSI Securities Corporation SSI 24,250 VND 28,021 VND +16%
Bolsas y Mercados Argentinos S.A BYMA 313.75 ARS 120.22 ARS -62%

Compare IPOPEMA Securities S.A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is IPOPEMA Securities S.A (IPE) overvalued or undervalued?
As of Jul 16, 2026, our model estimates a fair value of 6.34 PLN versus a price of 9.20 PLN, about −31% (overvalued).
What is the fair value of IPE?
Our model-based fair value for IPOPEMA Securities S.A is 6.34 PLN (as of Jul 16, 2026), built from audited fundamentals. The current price is 9.20 PLN.
What is the quality score of IPE?
IPOPEMA Securities S.A has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of IPOPEMA Securities S.A (IPE)?
IPOPEMA Securities S.A reported trailing-twelve-month revenue of about 269M PLN (latest available figure, as of Jul 16, 2026).
What is the net profit margin of IPE?
The net profit margin of IPOPEMA Securities S.A is about 3.4%, meaning it keeps roughly 3.4% of revenue as net income. Based on the latest reported figures.
Does IPOPEMA Securities S.A pay a dividend?
IPOPEMA Securities S.A currently shows a dividend yield of about 3.06% relative to its recent price (as of Jul 16, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track IPOPEMA Securities S.A and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.